Note: The following is an edited version of a press release from SigilonÂ Therapeutics.Â Read the press release from SigilonÂ TherapeuticsÂ in it’s entiretyÂ here.
Flagship Pioneering, a fully-integrated life science innovationÂ enterprise, recentlyÂ announced the launch of Sigilon Therapeutics Inc. Sigilon Therapeutics is aÂ biopharmaceutical company that discovers and develops category-defining biocompatible encapsulatedÂ cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionaryÂ biocompatible Afibromer™ technology, a new class of implantable biomaterials that do not triggerÂ fibrosis. The company will develop products that emerge from its discovery platform to treat seriousÂ hematologic, enzyme deficiency and endocrine disorders. VentureLabs®, Flagship’s institutionalÂ innovation foundry, originated Sigilon Therapeutics and co-founded the company with Professors DanielÂ Anderson and Robert Langer of MIT’s Institute of Medical Engineering and Science, Department ofÂ Chemical Engineering and Koch Institute.